Ipamorelin

Investigated uses

• No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.

Mechanism and hypotheses

• Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist with growth-hormone-releasing activity.
• Hypothesized: Claims of selective recovery, sleep or body-composition benefit are not supported by an approved indication or robust outcome trial.

Human evidence

• No qualifying controlled human efficacy study for the exact catalog identity/formulation was identified in this review. Limitations: This is a bounded search conclusion, not proof that no report exists; identity, language and indexing limitations may apply.

Safety highlights

• Human route-specific safety is limited; endocrine and gastrointestinal effects may occur.
• FDA notes serious adverse events, including deaths, in an intravenous gastrointestinal-motility study; causality and relevance to other routes are uncertain.

Regulatory context

No FDA-approved ipamorelin drug was identified; FDA lists ipamorelin among substances presenting significant compounding safety concerns.